Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated LDL-C. News about NewAmsterdam frequently centers on the clinical and regulatory progress of its lead investigational CETP inhibitor, obicetrapib, and related fixed-dose combination programs with ezetimibe.
Investors and clinicians following NAMS news can expect regular updates on NewAmsterdam’s Phase 3 development program, including the PREVAIL cardiovascular outcomes trial in patients with a history of atherosclerotic cardiovascular disease, the REMBRANDT imaging trial evaluating effects on coronary plaque and inflammation, and the RUBENS trial in patients with type 2 diabetes or metabolic syndrome who require additional LDL-C lowering. Press releases also cover pooled efficacy and safety data from pivotal trials such as BROOKLYN, BROADWAY and TANDEM, as presented at major cardiology and neurology conferences and in peer-reviewed journals.
Company news additionally includes regulatory milestones, such as acceptance of marketing authorization applications for obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination by the European Medicines Agency, as well as partnership activities with the Menarini Group in Europe and collaborations like the REMBRANDT imaging partnership with Caristo Diagnostics. Corporate updates on financial results, cash position, and equity-based inducement grants under Nasdaq Listing Rule 5635(c)(4) are also disclosed through press releases and SEC filings.
By monitoring NewAmsterdam Pharma news, readers can follow the evolution of obicetrapib’s clinical evidence in LDL-C lowering, cardiovascular outcomes, coronary plaque imaging and Alzheimer’s disease biomarkers, along with the company’s progress toward potential commercialization pathways and ongoing engagement with the investment and medical communities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NewAmsterdam Pharma has completed patient enrollment in the pivotal Phase 3 BROOKLYN clinical trial for obicetrapib, targeting adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels are inadequately managed despite maximal lipid-lowering therapy. The trial enrolled 354 participants across ten countries, with results expected in the second half of 2024. Obicetrapib, a next-generation CETP inhibitor, aims to offer improved options for HeFH patients. Previous Phase 2 trials showed significant LDL-C reduction of 51% and 59% in combination therapy. The rapid enrollment reflects a pressing unmet need for effective LDL-C management in the HeFH community.
NewAmsterdam Pharma Company (Nasdaq: NAMS) has announced the appointment of Janneke van der Kamp as an independent director on its Board of Directors. Ms. van der Kamp brings over two decades of pharmaceutical experience, particularly in cardiovascular disease. CEO Michael Davidson expressed optimism about her contributions as the company advances its clinical trials for obicetrapib. The company, focused on transforming therapies for metabolic diseases, is preparing for key regulatory milestones, building on promising clinical results showing significant LDL-C reductions with obicetrapib. NewAmsterdam recently completed a business combination with Frazier Lifesciences, raising approximately $328 million.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has successfully completed its business combination with FLAC and raised approximately $235 million through an oversubscribed PIPE financing, extending its cash runway through 2026. The company announced positive results from the Phase 2 ROSE2 trial, showing a 59% reduction in LDL-C when obicetrapib was combined with ezetimibe, and is set to present full data at the NLA Scientific Sessions in June 2023. Additionally, NewAmsterdam has initiated a Phase 2 study in Japan and is on track with three pivotal Phase 3 trials for obicetrapib. As of December 31, 2022, the company reported €439 million in cash and €98 million in revenue.